GSK's Lapatinib Found Effective in Breast Cancer Study
Posted on: Monday, 21 April 2008, 09:01 CDT
GlaxoSmithKline has announced final results from a prospective study which demonstrated that lapatinib decreases tumourigenic stem cells in primary breast cancers of women receiving neoadjuvant treatment.
In this study, 45 patients with locally advanced ErbB2 over-expressing breast cancer, received lapatinib before surgery, initially as a single agent for the first six weeks, followed by a combination of lapatinib plus weekly trastuzumab and three-weekly docetaxel for 12 weeks. Biopsies were taken at time of diagnosis and after six weeks of lapatinib, and assessed for tumourigenic cells.
Results showed significant tumor regression (median decrease of -60.8%, p=0.001) in primary tumors after only six weeks of single agent lapatinib. Unlike treatment with chemotherapy, lapatinib decreased tumorigenic breast cancer stem cells from 10.6% to 4.7%. The pathologic complete response rate following combination treatment (lapatinib plus trastuzumab and docetaxel) was 63%.
Steven Stein, vice president, Oncology Medicine Development Centre, GlaxoSmithKline, said: "For example, stem cell research may bring us closer towards understanding why, in some women, breast cancer can return after lying dormant for many years following full remission. We are encouraged by the data from this study and are committed to further investigations."
Source: Datamonitor
Related Articles
- Research Shows PET Can Measure Effectiveness Of Novel Breast Cancer Treatment
- Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
- Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
- Optimal Boost Approach to Breast Cancer Treatment Significantly Reduces Recurrence Rate and Increases Survival Rate
- New Breast Cancer Treatment May Reduce Radiation to Healthy Tissue, Study Shows
- First Three Patients Treated in Adipose Stem and Regenerative Cell Clinical Safety and Feasibility Study for Breast Reconstruction; Represents First Clinical Use of Cytori's Regenerative Cell Processing System
- Clinical Safety and Feasibility Study Initiated Using Adipose Stem and Regenerative Cells in Breast Reconstruction Procedures
- Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force
- New Breast, Cervical Cancer Treatment Program Comes to Oklahoma
- New Breast Cancer Treatment May Help Thousands of Women Get Back on Track Faster
 |
 |
User Comments (0)
RSS Feeds